/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company headquartered in Tarrytown, New York, with a market capitalization of around $62.3 billion. The company specializes in discovering, developing, manufacturing, and commercializing transformative medicines across a broad range of serious diseases, including eye diseases, allergy and inflammation, cancer, cardiovascular, neurological, infectious, hematologic, and rare diseases. A crucial competitive edge is its VelociSuite® technology platform, which accelerates the discovery and optimization of fully human and bispecific antibodies.
Regeneron Pharmaceuticals has experienced a challenging 2025 so far, with its shares declining 17.5% on a year-to-date (YTD) basis, falling starkly short of the 9.9% YTD gain of the S&P 500 Index ($SPX). Over the past 52 weeks, REGN stock dipped by 51%, whereas the benchmark climbed by 15.1%.
Narrowing the focus, REGN also trailed behind the iShares Biotechnology ETF (IBB), which rose by 4.7% in 2025, and down 6.4% over the past 52 weeks.
REGN’s underperformance reflects several key drivers, including mixed trial outcomes such as a disappointing COPD drug (itepekimab) data, which caused a sharp stock decline, regulatory delays (e.g., for Eylea HD), and competitive pressure from biosimilars.
For the current fiscal year, ending in December 2025, analysts expect Regeneron Pharmaceuticals’ EPS to decline 19.8% year over year (YoY) to $30.99, on a diluted basis. The company has a steady earnings surprise history. It has topped the Street’s bottom-line estimates in three of the past four quarters, while missing on one.
The stock has a consensus “Moderate Buy” rating overall – reflecting optimism with a dash of caution. Of the 27 analysts offering recommendations, 18 advise a “Strong Buy,” one has a “Moderate Buy,” seven analysts are on the sidelines, recommending a “Hold” rating, and one gives a “Moderate Sell” rating.
Over the past three months, sentiment around the stock has cooled, signaling a more cautious, slightly bearish tone. The consensus rating slipped from a “Strong Buy” to a “Moderate Buy,” reflecting tempered optimism. Analysts’ confidence softened subtly – “Strong Buy” recommendations dipped from 19 to 18, while “Moderate Buy” ratings fell from two to one. The shift suggests investors and analysts are recalibrating expectations, keeping a watchful eye on performance before regaining full conviction.
Recently, Jefferies lifted REGN’s price target to $831 from $813 while reiterating a “Buy” rating, citing positive Phase 3 NIMBLE trial results for cemdisiran in generalized Myasthenia Gravis.
The mean price target of $737.52 represents a 25.5% premium to REGN’s current price. The Street-high price target of $900 suggests an upside potential of 53.2%.
On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
